



## OPEN ACCESS

## EDITED BY

Samson Olaniyi,  
Ladoke Akintola University of Technology,  
Nigeria

## REVIEWED BY

Ebenezer Bonyah,  
University of Education, Winneba, Ghana  
Lijun Pei,  
Zhengzhou University, China  
Afeez Abidemi,  
Federal University of Technology, Nigeria

## \*CORRESPONDENCE

Oluwaseun F. Egbelowo  
✉ oluwaseun@aaims.edu.gh

RECEIVED 29 January 2023

ACCEPTED 14 April 2023

PUBLISHED 15 May 2023

## CITATION

Egbelowo OF, Munyaiki JB, Dlamini PG,  
Osaye FJ and Simelane SM (2023) Modeling  
visceral leishmaniasis and tuberculosis  
co-infection dynamics.

*Front. Appl. Math. Stat.* 9:1153666.  
doi: 10.3389/fams.2023.1153666

## COPYRIGHT

© 2023 Egbelowo, Munyaiki, Dlamini, Osaye  
and Simelane. This is an open-access article  
distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,  
distribution or reproduction in other forums is  
permitted, provided the original author(s) and  
the copyright owner(s) are credited and that  
the original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Modeling visceral leishmaniasis and tuberculosis co-infection dynamics

Oluwaseun F. Egbelowo<sup>1,2\*</sup>, Justin B. Munyaiki<sup>1</sup>,  
Phumlani G. Dlamini<sup>3</sup>, Fadekemi J. Osaye<sup>4</sup> and  
Simphiwe M. Simelane<sup>3</sup>

<sup>1</sup>Department of Mathematics and Applied Mathematics, University of the Western Cape, Bellville, South Africa, <sup>2</sup>DSI-NRF Centre of Excellence in Mathematical and Statistical Sciences (CoE-MaSS), Johannesburg, South Africa, <sup>3</sup>Department of Mathematics and Applied Mathematics, University of Johannesburg, Johannesburg, South Africa, <sup>4</sup>Department of Mathematics and Computer Science, Alabama State University, Montgomery, AL, United States

The co-infection of visceral leishmaniasis (VL) and tuberculosis (TB) patients pose a major public health challenge. In this study, we develop a mathematical model to study the transmission dynamics of VL and TB co-infection by first analyzing the VL and TB sub-models separately. The dynamics of these sub-models and the full co-infection model are determined based on the reproduction number. When the associated reproduction number ( $\mathcal{R}_1$ ) for the TB-only model and ( $\mathcal{R}_2$ ) for the VL-only are less than unity, the model exhibits backward bifurcation. If  $\max\{\mathcal{R}_1, \mathcal{R}_2\} = \mathcal{R}_1$ , then the TB-VL co-infection model exhibits backward bifurcation for values of  $\mathcal{R}_1$ . Furthermore, if  $\max\{\mathcal{R}_1, \mathcal{R}_2\} = \mathcal{R}_2$ , and by choosing the transmission probability,  $\beta_L$  as the bifurcation parameter, then the phenomenon of backward bifurcation occurs for values of  $\mathcal{R}_2$ . Consequently, the full model, whose associated reproduction number is  $\mathcal{R}_0$ , also exhibits backward bifurcation when  $\mathcal{R}_0 = 1$ . The equilibrium points and their stability for the models are determined and analyzed based on the magnitude of the respective reproduction numbers. Finally, some numerical simulations are presented to show the reliability of our theoretical results.

## KEYWORDS

visceral leishmaniasis, tuberculosis, Routh-Hurwitz criterion, backward bifurcation, stability analysis

## 1. Introduction

Leishmaniasis is a neglected tropical disease (NTD) that is transmitted by infected sandflies and is caused by obligate intracellular protozoans of the genus *Leishmania* [1]. There are more than 20 *Leishmania* species with three main forms of the disease: cutaneous leishmaniasis, mucocutaneous leishmaniasis, and visceral leishmaniasis, also known as kala-azar. Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and causes skin lesions, mainly ulcers, on exposed parts of the body, leaving life-long scars and serious disability or stigma. Mucocutaneous leishmaniasis (MCL) is the most disabling form of the disease, and it affects mostly the mucous membranes of the nose and mouth. Visceral leishmaniasis (VL) is the most fatal disease, causing enlargement of the spleen and liver [2]. It may cause epidemic outbreaks with a high mortality rate. A varying proportion of visceral cases may evolve into a cutaneous form known as post-kala-azar dermal leishmaniasis (PKDL), which requires lengthy and costly treatment [3, 4]. VL is responsible for nearly 48,000 deaths worldwide with 2,00,000–4,00,000 new cases annually [5]. If the disease is

not treated, the fatality rate in developing countries can be as high as 100% within 2 years. Most cases are seen in six countries—Bangladesh, Brazil, Ethiopia, India, South Sudan, and Sudan [5]. There are no vaccines available, and all the current drug treatments have serious limitations such as prolonged administration, high cost, drug resistance, and toxicity [6]. Treatment efficacy is further compromised in the case of co-infection with tuberculosis (TB).

Co-infection of visceral leishmaniasis and TB is very common, increasing public health problems in tropical and subtropical areas [7–9]. TB is caused by the bacterium *Mycobacterium tuberculosis* and is spread through the air. It is a leading cause of death worldwide, especially among people with compromised immune systems. It is also an immuno-suppressive condition that helps latent leishmaniasis progress to clinical leishmaniasis [10]. Similarly, visceral leishmaniasis can reactivate latent tuberculosis. However, there has been growing interest in repurposing existing drugs used to treat tuberculosis and leishmaniasis. When compared to developing new drugs from scratch, this approach has several advantages, including the availability of well-characterized drugs with established safety profiles, shorter development timelines, and lower costs [6, 11]. It is also worth noting that, while some TB drugs may have anti-*Leishmania* parasite activity, they are not a universal cure for both TB and leishmaniasis. Treatment for each disease should be tailored to the individual patient's needs, and co-infected people may require a combination of drugs to effectively treat both diseases. When considering co-infection of leishmaniasis and TB, research has shown that co-infected individuals tend to have more severe disease and poorer treatment outcomes than those infected with only one of the diseases. This underscores the need for a co-infection model to better understand the interactions between the two diseases and develop effective treatment strategies. Hence, we develop a new mathematical model of VL and TB co-infection.

Mathematical models are now a critical component in developing control and mitigation strategies for any potential infectious disease epidemic. Mathematical models are frequently used to capture the dynamics of disease at different phases in order to understand the spread of diseases within a population and build both short- and long-term management strategies. We can evaluate a variety of different control tactics in computer simulations before applying them in real life using well-parameterized mathematical models [12, 13]. Many mathematical models have been developed to successfully explain real-life situations and played a key role in public health efforts. Driessche and Watmough [14] provided a precise definition of the basic reproduction number for a general compartmental disease model based on a system of ordinary differential equations. Castillo-Chavez and Song [15] provided a comprehensive review of the dynamics and control of tuberculosis. Standard disease transmission and control models in which the majority of the population steadily grows over time are presented in [16, 17]. Establishing the stability properties of a dynamic system is a difficult problem in general. Hence, the direct Lyapunov method is a used approach to establish the local and global stabilities of these models. Korobeinikov [18, 19] presented a family of Lyapunov functions for three-compartment epidemiological models that appear to be useful for more complex models. Furthermore, mathematical models have been used to understand the dynamic transmission of diseases such as malaria [17, 20], hepatitis [21], tuberculosis [22], dengue [23], and COVID-19 [24], and to understand the underlying dynamics of the target-mediated

drug disposition [25–27]. Co-infections by multiple pathogens are common and theory predicts co-infections to have major consequences for both within- and between-host disease dynamics [17, 28]. The treatment of the co-infection of these diseases must be initiated in a systemic manner because their drugs do not always work well together. While some co-infection mathematical models have been developed and analyzed to understand the transmission dynamics of various diseases [3, 29, 30], such efforts for a mathematical model to understand the visceral leishmaniasis (VL) and tuberculosis (TB) co-infection have not taken place yet (to the best of our knowledge). Therefore, in this study, we develop and analyze a mathematical model designed to understand the dynamics of VL and TB co-infection.

The manuscript is organized as follows: Section 2 presents a development of the co-infection model. Section 3 presents the TB sub-model while Section 4 presents the VL sub-model. The full co-infection model with its analysis is provided in Section 5. Section 6 discusses the numerical results to validate the theoretical findings. Finally, Section 7 concludes key results found in the present study.

## 2. Model formulation

The formulation of this co-infection closely follows the epidemiological dynamics of the two diseases. The model analysis and methods are related to study carried out by Mwangi et al. [17] and Mtisi et al. [31]. Although similar to their study, the general approach herein is unique in its own right.

### 2.1. Basic framework

The model assumes that the human population is divided into, susceptible individuals ( $S$ ), who are those exposed to TB-only ( $E_T$ ), those who are infected with TB ( $I_T$ ), those who recover from TB infection with temporal immunity ( $R_T$ ), those infected with visceral leishmaniasis ( $I_L$ ), those who develop PKDL after the treatment of visceral ( $P_L$ ), visceral leishmaniasis infected individuals having TB symptoms ( $I_{TL}$ ), and then those who are recovered having permanent immunity to visceral leishmaniasis ( $R_L$ ). The total population size  $N(t)$  is given by

$$N(t) = S(t) + E_T(t) + I_T(t) + R_T(t) + I_L(t) + P_L(t) + I_{TL}(t) + R_L(t). \quad (1)$$

Similarly, the sandfly population is divided into two categories, susceptible sandflies  $S_V(t)$  and visceral leishmaniasis parasite-infected sandflies  $I_V(t)$  and hence,

$$N_V(t) = S_V(t) + I_V(t). \quad (2)$$

The force of infection associated with TB infection in humans is

$$\lambda_T = \frac{\beta_T c_T I_T}{N}, \quad (3)$$

where  $\beta_T$  is the TB transmission probability and  $c_T$  is per capital contact rate. Similarly, the force of infection associated with visceral leishmaniasis infection in humans is

$$\lambda_L = \frac{\beta_L c_L m I_V}{N}, \quad (4)$$

where  $c_L$  is the per capita biting rate of sandflies on humans,  $m$  is a modification parameter accounting for the relative risk of infectiousness of VL infected vector, and  $\beta_L$  is the transmission probability of VL per bite per human. Susceptible sandflies are recruited at a constant rate  $\Lambda_V$  and acquire leishmaniasis infection at an average rate of

$$\lambda_V = \frac{\beta_V c_L (I_L + I_{TL} + P_L)}{N}, \tag{5}$$

following contact with leishmaniasis-infected humans.  $\beta_V$  is the transmission probability for sandfly infection, and sandflies have a per capita natural mortality rate  $\mu_V$ .

We assume that susceptible individuals are recruited into the population at per capita rate  $\Lambda$  and there is a per capita natural mortality rate  $\mu$  in all the population classes. Susceptible individuals with TB enter the latency stage at rate  $\lambda_T$  and then progress to active TB at rate  $\kappa$ . Individuals latently infected with TB also progress to active TB as a result of re-infection at rate  $\psi \lambda_T$  with  $\psi \in (0, 1)$  since primary infection confers some degree of immunity. Individuals with TB suffer disease-induced death at rate  $d_T$  and recover at rate  $p$ . A fraction of individuals who recover from TB could be infected with TB at rate  $q(1 - f)$  or latently infected at rate  $qf$ . Individuals infected with VL-only are generated following infection at a rate  $\lambda_L$ . Infected individuals die due to VL at an average rate  $d_L$  or get treatment at an average rate  $\alpha_1$ . A fraction  $\sigma$  of those who get treated recover and acquire permanent immunity, while the other fraction  $(1 - \sigma)$  develops PKDL. Those individuals with PKDL get treated at an average rate  $\alpha_2$  or recover naturally at an average rate  $\theta$  and acquire permanent immunity in both cases. Individuals infected with TB can be infected with VL at rate  $\lambda_L$ , while individuals infected with VL can be infected with TB at rate  $\lambda_T$ .

## 2.2. The model

Putting the above formulations and assumptions together gives the following system of differential equations:

$$\begin{cases} \dot{S} = \Lambda - \lambda_T S - \lambda_L S - \mu S, \\ \dot{E}_T = \lambda_T S - \kappa E_T - \psi \lambda_T E_T + qf \lambda_T R_T + \lambda_T R_L - \mu E_T, \\ \dot{I}_T = \kappa E_T + \psi \lambda_T E_T + q(1 - f) \lambda_T R_T - p I_T - \lambda_L I_T - (\mu + d_T) I_T, \\ \dot{R}_T = p I_T - qf \lambda_T R_T - q(1 - f) \lambda_T R_T - \lambda_L R_T - \mu R_T, \\ \dot{I}_L = \lambda_L S + \lambda_L R_T - \sigma \alpha_1 I_L - (1 - \sigma) \alpha_1 I_L - \lambda_T I_L - (\mu + d_L) I_L, \\ \dot{P}_L = (1 - \sigma) \alpha_1 I_L - (\alpha_2 + \theta) P_L - \mu P_L, \\ \dot{R}_L = \sigma \alpha_1 I_L - \lambda_T R_L + (\alpha_2 + \theta) P_L - \mu R_L, \\ \dot{I}_{TL} = \lambda_L I_T + \lambda_T I_L - (\mu + d_T + d_L) I_{TL}, \\ \dot{S}_V = \Lambda_V - \lambda_V S_V - \mu_V S_V, \\ \dot{I}_V = \lambda_V S_V - \mu_V I_V. \end{cases} \tag{6}$$

The model diagram is shown in [Figure 1](#) and the model has initial conditions given by

$$\begin{cases} S(0) > 0, & E_T(0) \geq 0, & I_T(0) \geq 0, & R_T(0) \geq 0, & I_L(0) \geq 0, \\ P_L(0) \geq 0, & R_L(0) \geq 0, & I_{TL}(0) \geq 0, & S_V(0) > 0, & I_V(0) \geq 0. \end{cases} \tag{7}$$

The parameters and their values of the model are summarized in [Table 1](#).

## 2.3. Invariant region and positivity of solutions

The basic dynamical features of the co-infection model (6) are summarized in the following Lemma.

**Lemma 1.** *Let  $(S, E_T, I_T, R_T, I_L, P_L, R_L, I_{TL}, S_V, I_V)$  be the solution of the co-infection model (6) with initial conditions (7). The closed set*

$$\Omega = \Omega_H \times \Omega_V,$$

where

$$\begin{aligned} \Omega_H &= \left\{ (S + E_T + I_T + R_T + I_L + P_L + R_L + I_{TL}) \in \mathbb{R}_+^8 : N \leq \frac{\Lambda}{\mu} \right\}, \\ \Omega_V &= \left\{ (S_V + I_V) \in \mathbb{R}_+^2 : N_V \leq \frac{\Lambda_V}{\mu_V} \right\}, \end{aligned}$$

is positively invariant and attracting for the co-infection model (6).

*Proof.* Adding the first eight equations in system (6), we have

$$\begin{aligned} \frac{dN}{dt} &= \Lambda - \mu N - d_T I_T - d_L I_L \\ &\leq \Lambda - \mu N. \end{aligned}$$

The comparison theorem [33] can be used to show that

$$0 \leq N \leq N(0)e^{-\mu t} + \frac{\Lambda}{\mu} (1 - e^{-\mu t}).$$

Thus, as  $t \rightarrow \infty$ ,  $0 \leq N \leq \frac{\Lambda}{\mu}$ . This implies that  $\Omega_H$  is an attracting set with respect to the model (6). Similarly, adding the last two equations in system (6), we have

$$\frac{dN_V}{dt} = \Lambda_V - \mu_V N_V. \tag{8}$$


Similarly, it can be shown that as  $t \rightarrow \infty$ ,  $0 \leq N_V \leq \frac{\Lambda_V}{\mu_V}$  implying that  $\Omega_V$  is an attracting set with respect to model (6).

Thus, it follows that all possible solutions of the model (6) will enter the region

$$\Omega = \Omega_H \times \Omega_V. \tag{9}$$

□

**Lemma 2.** *Let the initial data be as given in 7. Then, the solution set  $\{S, E_T, I_T, R_T, I_L, P_L, R_L, I_{TL}, S_V, I_V\}$  of system (6) is positive for all  $t > 0$ .*



*Proof.* From the first equation of system (6), we have

$$\begin{aligned} \dot{S} &= \Lambda - \lambda_T S - \lambda_L S - \mu S \\ &\geq -\lambda_T S - \lambda_L S - \mu S. \end{aligned}$$

Simple integration techniques yields

$$S(t) \geq S(0)e^{-(\lambda_T + \lambda_L + \mu)t} > 0 \quad \text{since} \quad \lambda_T + \lambda_L + \mu > 0.$$

Similarly, it can be shown that the remaining variables are also positive for all  $t > 0$ .  $\square$

These lemmas verify that every solution of the co-infection model (6) with initial conditions in  $\Omega$  remains there for  $t > 0$ . Furthermore, in  $\Omega$ , the usual existence, uniqueness, and continuation results hold for the system so that the model system (6) is well posed mathematically and epidemiological. Thus, it is sufficient to consider the dynamics of the co-infection model (6) in  $\Omega$ .

Next, we consider the dynamics of the two sub-models, namely, TB-only and VL-only models. This will help to lay down the foundation for the qualitative analysis of the full co-infection model.

### 3. TB sub-model

The TB sub-model is given by

$$\begin{cases} \dot{S} = \Lambda - \lambda_T S - \mu S, \\ \dot{E}_T = \lambda_T S - \kappa E_T - \psi \lambda_T E_T + f q \lambda_T R_T - \mu E_T, \\ \dot{I}_T = \kappa E_T + \psi \lambda_T E_T + q(1-f)\lambda_T R_T - p I_T - (\mu + d_T) I_T, \\ \dot{R}_T = p I_T - q f \lambda_T R_T - q(1-f)\lambda_T R_T - \mu R_T, \end{cases} \quad (9)$$

with initial conditions (IC)

$$S(0) > 0, E_T(0) \geq 0, I_T(0) \geq 0, R_T(0) > 0. \quad (10)$$

Here, the total human population is  $N_T = S + E_T + I_T + R_T$ . The parameters of the TB sub-model are as described in Table 1. The basic dynamical features of the TB sub-model model (9) are summarized in the following Lemma.

**Lemma 3.** Let the solution of system (9) be  $(S, E_T, I_T, R_T)$  with initial conditions (10). The closed set

$$\mathcal{G}_{\mathcal{T}} = \left\{ S, E_T, I_T, R_T \in \mathbb{R}_{\geq 0} : N_T \leq \frac{\Lambda}{\mu} \right\}. \quad (11)$$

is positively invariant and attracting under the flow governed by model system (9).

*Proof.* Adding all the equations in the system (9), we obtain

$$\begin{aligned} \frac{dN_T}{dt} &= \Lambda - \mu N_T - d_T I_T, \\ &\leq \Lambda - \mu N_T. \end{aligned}$$

The comparison theorem can be used to show that

$$0 \leq N_T \leq N_T(0)e^{-\mu t} + \frac{\Lambda}{\mu} (1 - e^{-\mu t}).$$

Thus, as  $t \rightarrow \infty, 0 \leq N_T \leq \frac{\Lambda}{\mu}$ . This implies that  $\mathcal{G}_{\mathcal{T}}$  is an attracting set with respect to model (9).  $\square$

TABLE 1 Descriptions and values of parameters of the co-infection model (6).

Description	Parameter	Value	Unit	References
Recruitment rate	$\Lambda$	$\mu N$	$yr^{-1}$	[32]
Human natural mortality rate	$\mu$	0.002	$yr^{-1}$	[32]
Contact rate associated with TB	$c_T$	3/365	$yr^{-1}$	Assumed
Death rate due to TB	$d_T$	0.1	$yr^{-1}$	[32]
Probability of being infected	$\beta_T$	0.075	$yr^{-1}$	[32]
Natural rate of progression to active TB	$\kappa$	0.00913	$yr^{-1}$	[32]
Natural recovery rate	$p$	0.0005	$yr^{-1}$	Assumed
Relapsing rate	$q$	0.0001	$yr^{-1}$	[32]
Modification parameter	$\psi$	0.71	$yr^{-1}$	[32]
Death rate due to VL	$d_L$	0.00011	$yr^{-1}$	[3]
Recovering rate from VL after treatment	$\sigma$	0.5	$yr^{-1}$	[3]
Natural recovery rate from PKDL	$\alpha_2$	0.00556	$yr^{-1}$	[3]
Recovery rate from PKDL after treatment	$\theta$	0.003	$yr^{-1}$	[3]
Treatment rate of VL	$\alpha_1$	0.5	$yr^{-1}$	[3]
Transmission probability per bite per human	$\beta_L$	0.00055	$yr^{-1}$	[3]
Transmission probability for sandfly	$\beta_V$	0.0714	$yr^{-1}$	[3]
Biting rate of sandflies	$c_L$	0.002	$yr^{-1}$	[3]
Modification parameter	$m$	0.25	$yr^{-1}$	Assumed
Sandflies natural mortality rate	$\mu_V$	0.189	$yr^{-1}$	[3]
Sandflies recruitment rate	$\Lambda_V$	$\mu_V N_V$	$yr^{-1}$	Assumed

### 3.1. TB sub-model disease-free equilibrium

The disease-free equilibrium (DFE) for the TB sub-model (9) is given by

$$E_0 = \left( S_0, E_{T_0}, I_{T_0}, R_{T_0} \right) = \left( \frac{\Lambda}{\mu}, 0, 0, 0 \right). \tag{12}$$

According to the next-generation matrix approach in van den Driessche and Watmough [14], to compute the basic reproduction

of the TB sub-model, we set  $X = (E_T, I_T, R_T)^T$  and rewrite the model (9) in the matrix form

$$\frac{dX}{dt} = \mathcal{F}(X) - \mathcal{V}(X), \tag{13}$$

where

$$\mathcal{F} = \begin{bmatrix} \lambda_T S \\ 0 \\ 0 \end{bmatrix} \text{ and}$$

$$\mathcal{V} = \begin{bmatrix} \kappa E_T + \psi \lambda_T E_T - f q \lambda_T R_T + \mu E_T \\ -\kappa E_T - \psi \lambda_T E_T - q(1-f)\lambda_T R_T + p I_T + (\mu + d_T) I_T \\ -p I_T + q(1-f)\lambda_T R_T + \mu R_T \end{bmatrix}.$$

At the equilibrium point  $E_0$ , the Jacobian matrices of  $\mathcal{F}$  and  $\mathcal{V}$  are

$$F = \begin{bmatrix} 0 & \beta_T c_T & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \end{bmatrix} \text{ and } V = \begin{bmatrix} \kappa + \mu & 0 & 0 \\ -\kappa & p + \mu + d_T & 0 \\ 0 & -p & \mu \end{bmatrix}.$$

It follows that the TB sub-model reproduction number is given by

$$\mathcal{R}_1 = \frac{\kappa \beta_T c_T}{(\mu + \kappa)(\mu + d_T + p)}. \tag{14}$$

A value of  $\mathcal{R}_1$  less than one indicates that TB will be eliminated while a value greater than one indicates that a TB infection will continue to spread within the susceptible hosts.

**Theorem 1.** *The disease-free equilibrium point of the TB-only sub-model (9) is locally asymptotically stable if  $\mathcal{R}_1 < 1$  and unstable otherwise.*

*Proof.* The Jacobian matrix of model (9) at the disease-free equilibrium  $E_0$  is

$$J_0 = \begin{pmatrix} -\mu & 0 & -\beta_T c_T & 0 \\ 0 & -(\kappa + \mu) & \beta_T c_T & 0 \\ 0 & \kappa & -(p + \mu + d_T) & 0 \\ 0 & 0 & p & -\mu \end{pmatrix}. \tag{15}$$

The characteristic equation of matrix  $J_0$  is

$$(\lambda + \mu)^2 ((\kappa + \lambda + \mu)(d_T + \lambda + \mu + p) - \kappa c_T \beta_T) = 0, \tag{16}$$

where the eigenvalues can be obtained using the approach in [34]. Two eigenvalues of matrix  $J_0$  are  $-\mu$  (twice) and are both negative. The remaining two eigenvalues can be found by finding the eigenvalues of the sub-matrix

$$A = \begin{pmatrix} -(\kappa + \mu) & \beta_T c_T \\ \kappa & -(p + \mu + d_T) \end{pmatrix}. \tag{17}$$

By definition, the eigenvalues of matrix  $A$  are real and negative if  $tr(A) < 0$  and  $det(A) > 0$  (Routh-Hurwitz criterion). Thus, the trace and determinant of matrix  $A$  are

$$tr(A) = -d_T - \kappa - 2\mu - p, \tag{18}$$

$$\det(A) = (\kappa + \mu)(d_T + \mu + p) - \kappa c_T \beta_T, \\ = (\kappa + \mu)(p + \mu + d_T)(1 - \mathcal{R}_1), \tag{19}$$

respectively. Since all model parameters are assumed to be non-negative, it follows that  $tr(A) < 0$  regardless of the value of  $\mathcal{R}_1$ . We also have that  $\det(A) > 0$  if and only if  $\mathcal{R}_1 < 1$ .

Therefore, we conclude that if  $\mathcal{R}_1 < 1$ , then  $tr(A) < 0$  and  $\det(A) > 0$ , implying that all the eigenvalues of matrix  $J_0$  have a negative real part. The disease-free equilibrium  $\mathcal{R}_1$  is locally asymptotically stable. If  $\mathcal{R}_1 \geq 1$ , then  $\det(A) \leq 0$ , which proves the instability of  $E_0$ . □

### 3.2. Existence of the endemic equilibrium

The endemic equilibrium is the equilibrium (EE) of model (9) in which the infected component of the system is non-zero. The endemic equilibrium  $E_1 = (S_*, E_{T*}, I_{T*}, R_{T*})$  in terms of the force of infection  $\lambda_T^*$  is given by

$$S_* = \frac{\Lambda}{\lambda_T^* + \mu}, \\ E_{T*} = \frac{\lambda_T^* \Lambda (d_T(\mu + \lambda_T^* q) + f \lambda_T^* p q + \mu(\mu + p + \lambda_T^* q))}{(\lambda_T^* + \mu) (d_T(\mu + \lambda_T^* q)(\kappa + \lambda_T^* \psi + \mu) + \mu(p(f \lambda_T^* q + \kappa + \lambda_T^* \psi + \mu) + (\mu + \lambda_T^* q)(\kappa + \lambda_T^* \psi + \mu)))}, \\ I_{T*} = \frac{\lambda_T^* \Lambda (\kappa + \lambda_T^* \psi)(\mu + \lambda_T^* q)}{(\lambda_T^* + \mu) (d_T(\mu + \lambda_T^* q)(\kappa + \lambda_T^* \psi + \mu) + \mu(p(f \lambda_T^* q + \kappa + \lambda_T^* \psi + \mu) + (\mu + \lambda_T^* q)(\kappa + \lambda_T^* \psi + \mu)))}, \\ R_{T*} = \frac{\lambda_T^* \Lambda p (\kappa + \lambda_T^* \psi)}{(\lambda_T^* + \mu) (d_T(\mu + \lambda_T^* q)(\kappa + \lambda_T^* \psi + \mu) + \mu(p(f \lambda_T^* q + \kappa + \lambda_T^* \psi + \mu) + (\mu + \lambda_T^* q)(\kappa + \lambda_T^* \psi + \mu)))},$$

where

$$\lambda_T^* = \frac{\beta_T c_T I_{T*}}{N_{T*}}. \tag{20}$$

Substituting  $E_1$  into Equation (20) and simplifying yields the cubic equation

$$a_0 \lambda_T^{*3} + a_1 \lambda_T^{*2} + a_2 \lambda_T^* + a_3 = 0, \tag{21}$$

where

$$a_0 = q \psi, \\ a_1 = \psi(-\beta_T c_T q + \mu + p + \mu q) + q(\psi + 1)d_T + q(fp + \kappa + \mu), \\ a_2 = -c_T \beta_T (\mu \psi + \kappa q) + d_T (\mu \psi + \mu + q(\kappa + \mu)) \\ + p(\mu(fq + \psi + 1) + \kappa) + \mu(\mu \psi + (q + 1)(\kappa + \mu)), \\ a_3 = \mu(\mu + \kappa)(p + \mu + d_T)(1 - \mathcal{R}_1).$$

Thus, the endemic equilibrium  $E_1$  of the TB sub-model is obtained by solving Equation (21) for positive  $\lambda_T^*$  and substituting back into the equations in  $E_1$ . The number of possible positive real roots of the cubic polynomial Equation (21) depends on the signs of  $a_0, a_1, a_2$ , and  $a_3$ . We investigate this by using the Descartes rule of signs. The rule asserts that the number of positive roots is at most the number of sign changes in the sequence of polynomial coefficients. The possibilities are illustrated in Table 2.

The outcomes are established in the following theorem.

**Theorem 2.** *The TB sub-model (9) has the following features:*

TABLE 2 Number of possible positive roots of the cubic polynomial (21).

Cases	$a_0$	$a_1$	$a_2$	$a_3$	$\mathcal{R}_1$	Changes in sign	Total positive roots
1	+	-	-	-	$\mathcal{R}_1 > 1$	1	1
2	+	+	-	-	$\mathcal{R}_1 > 1$	1	1
3	+	+	+	-	$\mathcal{R}_1 > 1$	1	1
4	+	-	+	-	$\mathcal{R}_1 > 1$	3	3 or 1
5	+	-	-	+	$\mathcal{R}_1 < 1$	2	2 or 0
6	+	+	-	+	$\mathcal{R}_1 < 1$	2	2 or 0
7	+	-	+	+	$\mathcal{R}_1 < 1$	2	2 or 0
8	+	+	+	+	$\mathcal{R}_1 < 1$	0	0

1. A unique endemic equilibrium when  $\mathcal{R}_1 > 1$  and cases 1–3 hold.
2. One or more endemic equilibrium when  $\mathcal{R}_1 > 1$  and case 4 holds, as well as when  $\mathcal{R}_1 < 1$  and cases 5–7 hold.
3. No endemic equilibrium when  $\mathcal{R}_1 < 1$  and case 8 holds. This is the case when all coefficients are positive.

### 3.3. Backward bifurcation

For model (9), the existence of multiple TB persistence equilibria  $E_1$  for  $\mathcal{R}_1$  suggests the possibility of the backward bifurcation phenomenon. Epidemiologically, it suggests that  $\mathcal{R}_1$  may not be sufficient to decide whether or not TB would persist in the population. Instead, it depends on the initial population size of the individuals when  $\mathcal{R}_1 < 1$ . We investigate and set a threshold for the presence of backward bifurcation in system (9).

From Theorem 1 and 2, we see that if we consider  $\mathcal{R}_1$  as a bifurcation parameter, then there is an exchange of stability properties between equilibrium  $E_0$  and  $E_1$  at  $\mathcal{R}_1 = 1$ . We investigate the nature of bifurcation involving  $E_0$  at  $\mathcal{R}_1 = 1$  based on the use of the center manifold theory [15]. First, consider the case when  $\mathcal{R}_1 = 1$  and solve for  $\beta_T$  to obtain

$$\beta_T = \beta_T^* = \frac{(\kappa + \mu)(d_T + \mu + p)}{c_T \kappa}.$$

The  $\beta_T = \beta_T^*$  is chosen as the bifurcation parameter. Furthermore, the Jacobian of system (9) evaluated at  $E_0$  with  $\beta_T = \beta_T^*$  is given by

$$J(E_0, \beta_T^*) = \begin{pmatrix} -\mu & 0 & -\frac{(\kappa + \mu)(p + \mu + d_T)}{\kappa} & 0 \\ 0 & -\kappa - \mu & \frac{(\kappa + \mu)(p + \mu + d_T)}{\kappa} & 0 \\ 0 & \kappa & -p - \mu - d_T & 0 \\ 0 & 0 & p & -\mu \end{pmatrix}.$$



The  $J(E_0, \beta_T^*)$  has only one eigenvalue with zero real part. This then implies that the model (9) with  $\beta_T = \beta_T^*$  has at least one non-hyperbolic equilibrium point. We then use the center manifold approach to further analyze the dynamics of model (9). Corresponding to the zero eigenvalue, the Jacobian  $J(E_0, \beta_T^*)$  has a right eigenvector given by  $w = (w_1, w_2, w_3, w_4)^T$ , where

$$\begin{aligned} w_1 &= -\frac{(\kappa + \mu)}{\mu}w_2, & w_3 &= \frac{\kappa}{d_T + \mu + p}w_2, \\ w_4 &= \frac{\kappa p}{\mu(d_T + \mu + p)}w_2, & w_2 &> 0, \end{aligned}$$

and a left eigenvector given by  $v = (v_1, v_2, v_3, v_4)^T$ , where

$$v_1 = v_4 = 0, \quad v_3 = \frac{\kappa + \mu}{\kappa}v_2, \quad v_2 > 0.$$

We then follow the analysis as carried out by [16, 17]. Compute the coefficients  $\hat{a}$  and  $\hat{b}$  defined in theorem 4.1 by Castillo-Chavez and Song [15].

### Computation of $\hat{a}$ and $\hat{b}$

The  $\hat{a}$  and  $\hat{b}$  are given by

$$\begin{aligned} \hat{a} &= \sum_{k,i,j=1}^4 v_k w_i w_j \left. \frac{\partial^2 f_k}{\partial x_i \partial x_j} \right|_{E_0}, \\ \hat{b} &= \sum_{k,i=1}^4 v_k w_i \left. \frac{\partial^2 f_k}{\partial x_i \partial \beta_T} \right|_{E_0}. \end{aligned}$$

We use the center manifold approach on the model system (9). Let  $S = x_1, E = x_2, I = x_3$ , and  $R = x_4$ . Then  $N = x_1 + x_2 + x_3 + x_4$  so that

$$\begin{aligned} \dot{x}'_1 = f_1 &= \Lambda - \frac{\beta_T c_T x_3 x_1}{x_1 + x_2 + x_3 + x_4} - \mu x_1, \\ \dot{x}'_2 = f_2 &= \frac{\beta_T c_T x_3 x_1}{x_1 + x_2 + x_3 + x_4} - \kappa x_2 - \frac{\psi \beta_T c_T x_3 x_2}{x_1 + x_2 + x_3 + x_4} \\ &+ \frac{qf \beta c x_3 x_4}{x_1 + x_2 + x_3 + x_4} - \mu x_2, \\ \dot{x}'_3 = f_3 &= \kappa x_2 + \frac{\psi \beta_T c_T x_3 x_2}{x_1 + x_2 + x_3 + x_4} + \frac{q(1-f)\beta_T c_T x_3 x_4}{x_1 + x_2 + x_3 + x_4} \\ &- p x_3 - (\mu + d_T)x_3, \\ \dot{x}'_4 = f_4 &= p x_3 - \frac{qf \beta_T c_T x_3 x_4}{x_1 + x_2 + x_3 + x_4} - \frac{q(1-f)\beta_T c_T x_3 x_4}{x_1 + x_2 + x_3 + x_4} - \mu x_4. \end{aligned}$$

The associated non-zero partial derivatives of  $f_i = (f_1, f_2, f_3, f_4)^T$  at  $E_0$  are given by

$$\begin{aligned} \frac{\partial^2 f_2}{\partial x_2 \partial x_3} &= \frac{\partial^2 f_2}{\partial x_3 \partial x_2} = -\frac{c_T \beta_T \mu (1 + \psi)}{\Lambda}, \\ \frac{\partial^2 f_2}{\partial x_3^2} &= -\frac{2c_T \beta_T \mu}{\Lambda}, \\ \frac{\partial^2 f_2}{\partial x_3 \partial x_4} &= \frac{\partial^2 f_2}{\partial x_4 \partial x_3} = \frac{c_T (fq - 1) \beta_T \mu}{\Lambda}, \\ \frac{\partial^2 f_3}{\partial x_2 \partial x_3} &= \frac{\partial^2 f_3}{\partial x_3 \partial x_2} = \frac{c_T \beta_T \psi \mu}{\Lambda}, \end{aligned}$$

$$\frac{\partial^2 f_3}{\partial x_3 \partial x_4} = \frac{\partial^2 f_3}{\partial x_4 \partial x_3} = \frac{c_T (1-f) \beta_T q \mu}{\Lambda}.$$

Using the above expressions, the coefficients  $\hat{a}$  is given by

$$\begin{aligned} \hat{a} &= v_2 \sum_{i,j=1}^4 w_i w_j \frac{\partial^2 f_2}{\partial x_i \partial x_j} + v_3 \sum_{i,j=1}^4 w_i w_j \frac{\partial^2 f_3}{\partial x_i \partial x_j} \\ &= \frac{2\mu d_T}{\Lambda(\mu + d_T + p)} \left[ \frac{\mu \psi \beta_T c_T}{d_T(\kappa + \mu)} \right. \\ &\left. - \mathcal{R}_1 \left( 1 + \frac{\mu(\kappa + \mu) + p(\kappa - q\kappa + \mu - (1-f)q\mu)}{\mu d_T} \right) \right] v_2 w_2^2. \end{aligned}$$

For the sign of  $\hat{b}$ , we chose  $\beta_T$  as the bifurcation parameter and it can be shown that the associated non-zero partial derivatives of  $f_i$  at  $E_0$  are given by

$$\frac{\partial^2 f_1}{\partial x_3 \partial \beta_T} = -c_T, \quad \frac{\partial^2 f_2}{\partial x_3 \partial \beta_T} = c_T,$$

so that

$$\hat{b} = v_2 w_3 \frac{\partial^2 f_2}{\partial x_3 \partial \beta_T} = \frac{c_T \kappa}{d_T + \mu + p} v_2 w_2.$$

It is seen that  $\hat{b}$  is always positive, while  $\hat{a}$  can either be positive or negative. Depending on the signs of  $\hat{a}$  and  $\hat{b}$ , we establish the following lemmas

Lemma 4. If  $\hat{a} < 0$  and  $\hat{b} > 0$ , then the TB sub-model model (9) undergoes forward bifurcation which occurs at  $\mathcal{R}_1 = 1$ .

Lemma 5. If  $\hat{a} > 0$  and  $\hat{b} > 0$ , then the TB sub-model model (9) undergoes backward bifurcation which occurs at  $\mathcal{R}_1 = 1$ .

Hence, the positivity of  $\hat{a}$  offers the threshold circumstance for the phenomenon of backward bifurcation.

## 4. Visceral leishmaniasis sub-model

The visceral leishmaniasis (VL) sub-model is given by

$$\begin{cases} \dot{S} = \Lambda - \lambda_L S - \mu S, \\ \dot{I}_L = \lambda_L S - \sigma \alpha_1 I_L - (1 - \sigma) \alpha_1 I_L - (\mu + d_L) I_L, \\ \dot{P}_L = (1 - \sigma) \alpha_1 I_L - (\alpha_2 + \theta) P_L - \mu P_L, \\ \dot{R}_L = \sigma \alpha_1 I_L + (\alpha_2 + \theta) P_L - \mu R_L, \\ \dot{S}_V = \Lambda_V - \lambda_V S_V - \mu_V S_V, \\ \dot{I}_V = \lambda_V S_V - \mu_V I_V. \end{cases} \tag{22}$$

The force of VL infection in humans is  $\lambda_L = \frac{\beta_{LC} m I_V}{N_L}$ . Susceptible individuals are infected with visceral leishmaniasis following contact with infected sandflies at a per capita rate  $\lambda_V = \frac{\beta_V c_V (I_L + P_L)}{N_L}$ . Here, we have that the total human population is  $N_L = S + I_L + P_L + R_L$ . The total human population dynamics for the VL sub-model are given by

$$\dot{N}_L = \Lambda - \mu N_L - d_L I_L. \tag{23}$$

Given that the initial conditions are non-negative, i.e.,  $N_L(0) \geq 0$ , the total human population is positive and bounded for all finite time  $t > 0$ . The dynamics of the sandflies population are given by

$$\dot{N}_V = \Lambda_V - \mu_V N_V. \tag{24}$$

We conclude that all feasible solutions for the human population enter the region

$$\mathcal{G}_{\mathcal{L}} = \left\{ S, I_L, P_L, R_L \in \mathbb{R}_{\geq 0} : 0 \leq N_L \leq \frac{\Lambda}{\mu} \right\}, \tag{25}$$

while feasible solutions for the sandflies population entering the region,

$$\mathcal{G}_{\mathcal{V}} = \left\{ S_V, I_V \in \mathbb{R}_{\geq 0} : 0 \leq N_V \leq \frac{\Lambda_V}{\mu_V} \right\}. \tag{26}$$

$$J_1 = \begin{pmatrix} -\mu & 0 & 0 & 0 & 0 & 0 & -\beta_L c_L m \\ 0 & -(\mu + d_L + (1 - \sigma)\alpha_1 + \sigma\alpha_1) & 0 & 0 & 0 & 0 & \beta_L c_L m \\ 0 & (1 - \sigma)\alpha_1 & -(\alpha_2 + \theta + \mu) & 0 & 0 & 0 & 0 \\ 0 & \sigma\alpha_1 & \alpha_2 + \theta & -\mu & 0 & 0 & 0 \\ 0 & \frac{\beta_V c_L \Lambda_V \mu}{\mu_V \Lambda} & \frac{\beta_V c_L \Lambda_V \mu}{\mu_V \Lambda} & 0 & -\mu_V & 0 & 0 \\ 0 & \frac{\mu_V \Lambda}{\beta_V c_L \Lambda_V \mu} & \frac{\mu_V \Lambda}{\beta_V c_L \Lambda_V \mu} & 0 & 0 & -\mu_V & 0 \\ 0 & \frac{\beta_V c_L \Lambda_V \mu}{\mu_V \Lambda} & \frac{\beta_V c_L \Lambda_V \mu}{\mu_V \Lambda} & 0 & 0 & 0 & -\mu_V \end{pmatrix}. \tag{30}$$

### 4.1. The disease-free equilibrium

The disease-free equilibrium (DFE) for the VL-only model is given by

$$\mathcal{Q}_0 = \left( S, I_L, P_L, R_L, S_V, I_V \right) = \left( \frac{\Lambda}{\mu}, 0, 0, 0, \frac{\Lambda_V}{\mu_V}, 0 \right). \tag{27}$$

According to the next-generation matrix approach, to compute the basic reproduction of the VL sub-model we set  $X = (I_L, P_L, R_T, S, I_V, S_V)^T$  and rewrite the model (22) in the matrix form

$$\frac{dX}{dt} = \mathcal{F}(X) - \mathcal{V}(X), \tag{28}$$

where

$$\mathcal{F} = \begin{bmatrix} \lambda_L S \\ 0 \\ \lambda_V S_V \end{bmatrix} \text{ and } \mathcal{V} = \begin{bmatrix} \sigma\alpha_1 I_L + (1 - \sigma)\alpha_1 I_L + (\mu + d_L)I_L \\ (\alpha_2 + \theta + \mu)P_L - (1 - \sigma)\alpha_1 I_L \\ \mu_V I_V \end{bmatrix}.$$

At the equilibrium point  $\mathcal{Q}_0$ , the Jacobian matrices of  $\mathcal{F}$  and  $\mathcal{V}$  are

$$F = \begin{bmatrix} 0 & 0 & \beta_L c_L m \\ 0 & 0 & 0 \\ \frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & \frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & 0 \end{bmatrix} \text{ and}$$

$$V = \begin{bmatrix} \alpha_1 + \mu + d_L & 0 & 0 \\ -(1 - \sigma)\alpha_1 & \alpha_2 + \theta + \mu & 0 \\ 0 & 0 & \mu_V \end{bmatrix}.$$

As such, the VL sub-model reproduction number is given by

$$\mathcal{R}_2 = \sqrt{\frac{\mu m c_L^2 \beta_L \beta_V \Lambda_V (\alpha_1 (1 - \sigma) + \alpha_2 + \theta + \mu)}{\Lambda \mu_V^2 (\alpha_2 + \theta + \mu) (\alpha_1 + d_L + \mu)}}. \tag{29}$$

**Theorem 3.** *The disease-free equilibrium point of the VL-only sub-model (22) is locally asymptotically stable if  $\mathcal{R}_2 < 1$  and unstable when  $\mathcal{R}_2 > 1$ .*

*Proof.* The Jacobian of model (22) at the disease-free equilibrium  $\mathcal{Q}_0$  is

The matrix  $J_1$  has three negative eigenvalues  $-\mu$  (twice) and  $\mu_V$ . The remaining eigenvalues are found by finding the eigenvalues of

$$B = \begin{pmatrix} -(\mu + d_L + (1 - \sigma)\alpha_1 + \sigma\alpha_1) & 0 & \beta_L c_L m \\ (1 - \sigma)\alpha_1 & -(\alpha_2 + \theta + \mu) & 0 \\ \frac{\beta_V c_L \Lambda_V \mu}{\mu_V \Lambda} & -\frac{\beta_V c_L \Lambda_V \mu}{\mu_V \Lambda} & -\mu_V \end{pmatrix}. \tag{31}$$

The characteristic polynomial of  $B$  is

$$\lambda^3 + a_2 \lambda^2 + a_1 \lambda + a_0 = 0, \tag{32}$$

where

$$\begin{aligned} a_2 &= \alpha_1 + \alpha_2 + d_L + \theta + 2\mu + \mu_V, \\ a_1 &= -\frac{\mu m c_L^2 \beta_L \beta_V \Lambda_V}{\Lambda \mu_V} + (\alpha_2 + \theta + \mu) (\alpha_1 + d_L + \mu) \\ &\quad + \mu_V (\alpha_1 + \alpha_2 + d_L + \theta + 2\mu), \\ a_0 &= (\mu + d_L + \alpha_1) (\theta + \alpha_2 + \mu) [1 - \mathcal{R}_2^2]. \end{aligned}$$

The Routh-Hurwitz criteria reveals that the roots of polynomial (32) have negative real parts if

$$a_0 > 0, a_2 > 0, a_2 a_1 > a_0.$$

We observe that  $a_2 > 0$  always and  $a_0 > 0$  if  $\mathcal{R}_2 < 1$ . With a simple expansion, we can show that  $a_2 a_1 > a_0$  (i.e.,  $a_2 a_1 - a_0 > 0$ ) if  $\mathcal{R}_2 < 1$ . Therefore, the disease-free equilibrium  $\mathcal{Q}_0$  is locally stable when  $\mathcal{R}_2 < 1$ .  $\square$



### 4.2. Existence of the endemic equilibrium

The endemic equilibrium of model (22) is given by  $E_2 = (\hat{S}, \hat{I}_L, \hat{P}_L, \hat{R}_L, \hat{S}_V, \hat{I}_V)$  as functions of the forces of infection  $\hat{\lambda}_L$  and  $\hat{\lambda}_V$

$$\begin{aligned} \hat{S} &= \frac{\Lambda}{\mu + \lambda_L}, \\ \hat{I}_L &= \frac{\Lambda \lambda_L}{(\mu + \lambda_L)(\alpha_1 + d_L + \mu)}, \\ \hat{P}_L &= \frac{\alpha_1 \Lambda (1 - \sigma) \lambda_L}{(\alpha_2 + \theta + \mu)(\mu + \lambda_L)(\alpha_1 + d_L + \mu)}, \\ \hat{R}_L &= \frac{\alpha_1 \Lambda \lambda_L (\alpha_2 + \theta + \mu \sigma)}{\mu (\alpha_2 + \theta + \mu)(\mu + \lambda_L)(\alpha_1 + d_L + \mu)}, \\ \hat{S}_V &= \frac{\Lambda_V}{\lambda_V + \mu_V}, \\ \hat{I}_V &= \frac{\lambda_V \Lambda_V}{\mu_V (\lambda_V + \mu_V)}, \end{aligned}$$

where

$$\hat{\lambda}_L = \frac{\beta_L c_L m \hat{I}_V}{\hat{N}_L} \quad \text{and} \quad \hat{\lambda}_V = \frac{\beta_V c_L (\hat{I}_L + \hat{P}_L)}{\hat{N}_L}. \tag{33}$$

Substituting  $E_2$  into Equation (33) and simplifying yields the quadratic equation

$$a \hat{\lambda}_L^2 + b \hat{\lambda}_L + c = 0, \tag{34}$$

where

$$a = \Lambda (\alpha_1 + \mu) \mu_V (\mu c_L \beta_V (\alpha_1 (1 - \sigma) + \alpha_2 + \theta + \mu) + (\alpha_1 + \mu) \mu_V (\alpha_2 + \theta + \mu)), \tag{35}$$

$$b = \Lambda \mu \mu_V^2 (\alpha_1 + d_L + \mu)^2 (\alpha_2 + \theta + \mu) \left[ \frac{2(\mu + \alpha_1)}{\alpha_1 + d_L + \mu} + \mathcal{R}_2^2 \left( \frac{\Lambda \mu_V}{m \beta_L c_L \Lambda_V} - 1 \right) \right], \tag{36}$$

$$c = \Lambda \mu^2 \mu_V^2 (\alpha_1 + d_L + \mu)^2 (\alpha_2 + \theta + \mu) (1 - \mathcal{R}_2^2). \tag{37}$$

Therefore, the endemic equilibrium  $E_2$  of the VL sub-model (22) is obtained by solving Equation (34) for positive  $\lambda^*$  and substituting back into the equations in  $E_2$ . To find the solutions of Equation (34), we make the following observations:  $a$  is always positive, while  $b$  and  $c$  may be positive or negative depending on the signs of  $\mathcal{R}_2$ , i.e., we have

$$a > 0, \quad b = \begin{cases} > 0 \\ < 0 \end{cases} \quad \text{and} \quad c = \begin{cases} > 0 \text{ if } \mathcal{R}_2 < 1 \\ < 0 \text{ if } \mathcal{R}_2 > 1. \end{cases} \tag{38}$$

From Equation (38), five cases in determining the solution/roots of Equation (34) arise:

- (i) Case 1: If  $\mathcal{R}_2 < 1$ , then  $c > 0$  and so Equation (34) has two positive roots when  $b < 0$ .

$$J(E_1, \beta_1^*) = \begin{pmatrix} -\mu & 0 & 0 & 0 & 0 & -\frac{\Lambda(\mu+d_L+\alpha_1)(\theta+\mu+\alpha_2)\mu_V^2}{\mu c_L(\theta+\mu(1-\sigma)\alpha_1+\alpha_2)\beta_V\Lambda_V} \\ 0 & -\mu - d_L - (1-\sigma)\alpha_1 - \sigma\alpha_1 & 0 & 0 & 0 & \frac{\Lambda(\mu+d_L+\alpha_1)(\theta+\mu+\alpha_2)\mu_V^2}{\mu c_L(\theta+\mu(1-\sigma)\alpha_1+\alpha_2)\beta_V\Lambda_V} \\ 0 & (1-\sigma)\alpha_1 & -\theta - \mu - \alpha_2 & 0 & 0 & 0 \\ 0 & \sigma\alpha_1 & \theta + \alpha_2 & -\mu & 0 & 0 \\ 0 & -\frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & -\frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & 0 & -\mu_V & 0 \\ 0 & \frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & \frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & 0 & 0 & -\mu_V \end{pmatrix}.$$

- (ii) Case 2: If  $\mathcal{R}_2 < 1$ , then  $c > 0$  and so Equation (34) has no positive roots (two negative roots) when  $b < 0$ .
- (iii) Case 3: If  $\mathcal{R}_2 > 1$ , then  $c < 0$  and so Equation (34) has one positive root when  $b > 0$ .
- (iv) Case 4: If  $\mathcal{R}_2 > 1$ , then  $c < 0$  and so Equation (34) also has one positive root when  $b < 0$ .
- (v) Case 5: When  $\mathcal{R}_2 = 1$ , Equation (34) reduces to  $\hat{\lambda}_L(a\hat{\lambda} + b) = 0$ , at which  $\hat{\lambda}_L = 0$  (corresponding to the disease-free equilibrium  $Q_0$ ) and  $\hat{\lambda}_L = \frac{-b}{a}$  is a positive root when  $b < 0$  and negative root (biologically meaningless) when  $b > 0$ .

Furthermore, the critical value of  $\mathcal{R}_2$  denoted by  $\mathcal{R}_c$  in the case when  $\mathcal{R}_2 < 1$  is found by setting the discriminant  $\Delta = b^2 - 4ac$  to be zero. This yields

$$\mathcal{R}_c = \sqrt{1 - \frac{b^2}{4a\Lambda\mu^2\mu_V^2(\alpha_1 + d_L + \mu)^2(\alpha_2 + \theta + \mu)}}. \tag{39}$$

Thus, the following connections hold

- $\Delta < 0 \iff \mathcal{R}_2 < \mathcal{R}_c$ .
- $\Delta = 0 \iff \mathcal{R}_2 = \mathcal{R}_c$ .
- $\Delta > 0 \iff \mathcal{R}_2 > \mathcal{R}_c$ .

It can be shown that backward bifurcation occurs for values of  $\mathcal{R}_2$  such that  $\mathcal{R}_c < \mathcal{R}_2 < 1$ . The existence of the endemic equilibrium of model (22) is summarized as follows:

Theorem 4. *The VL sub-model (22) has those as follows:*

1. a unique endemic equilibrium if  $\mathcal{R}_2 > 1$ ;
2. two endemic equilibria exists, one of which is locally stable, if  $b < 0$  and  $\mathcal{R}_2 < 1$ ;
3. otherwise, the DFE is the only unique attractor if  $\mathcal{R}_2 < 1$ .

From Theorems 3 and 4, model (22) has the usual bifurcation at  $\mathcal{R}_2 = 1$ . If we consider  $\mathcal{R}_2$  as the bifurcation parameter, then by definition, there is a switch in stability properties between equilibrium point  $Q_0$  and  $E_2$  at  $\mathcal{R}_2 = 1$ . Under certain conditions, model (22) exhibits a backward bifurcation, in which the endemic equilibrium exists for  $\mathcal{R}_2 < 1$ . Setting  $\mathcal{R}_2 = 1$  and solving for  $\beta_L$  yields

$$\beta_L = \beta_L^* = \frac{\Lambda \mu_V^2 (\alpha_2 + \theta + \mu) (\alpha_1 + d_L + \mu)}{\mu m c_L^2 \beta_V \Lambda_V (\alpha_1 (1 - \sigma) + \alpha_2 + \theta + \mu)},$$

and  $\beta_L = \beta_L^*$  is chosen as the bifurcation parameter.

Determining the conditions for the nature of bifurcation using center manifold theory follows as outlined in the sections above. The Jacobian of the system (22) evaluated at  $E_1$  with  $\beta_L = \beta_L^*$  is given by

The Jacobian  $J(E_1, \beta_L^*)$  has a right eigenvector given by  $w = (w_1, w_2, w_3, w_4, w_5, w_6)^T$ , where

$$\begin{aligned} w_1 &= -\frac{(\alpha_1 + d_L + \mu)}{\mu} w_2, & w_3 &= \frac{\alpha_1(1 - \sigma)}{\alpha_2 + \theta + \mu} w_2, \\ w_4 &= \frac{\alpha_1(\alpha_2 + \theta + \mu\sigma)}{\mu(\alpha_2 + \theta + \mu)} w_2, & w_5 &> 0, \\ w_5 &= -\frac{\mu c_L \beta_V \Lambda_V (\alpha_1(1 - \sigma) + \alpha_2 + \theta + \mu)}{\Lambda \mu_V^2 (\alpha_2 + \theta + \mu)} w_2, \\ w_6 &= \frac{\mu c_L \beta_V \Lambda_V (\alpha_1(1 - \sigma) + \alpha_2 + \theta + \mu)}{\Lambda \mu_V^2 (\alpha_2 + \theta + \mu)} w_2, \end{aligned}$$

and a left eigenvector given by  $v = (v_1, v_2, v_3, v_4, v_5, v_6)^T$ , where,

$$\begin{aligned} v_1 = v_4 = v_5 = 0, & \quad v_3 = \frac{(\alpha_1 + d_L + \mu)}{\alpha_1(1 - \sigma) + \alpha_2 + \theta + \mu} v_2, \\ v_6 &= \frac{\Lambda \mu_V (\alpha_2 + \theta + \mu) (\alpha_1 + d_L + \mu)}{\mu c_L \beta_V \Lambda_V (\alpha_1(1 - \sigma) + \alpha_2 + \theta + \mu)} v_2, \quad v_2 > 0. \end{aligned}$$

### Computation of $\hat{a}$ and $\hat{b}$

The  $\hat{a}$  and  $\hat{b}$  are given by

$$\begin{aligned} \hat{a} &= \sum_{k,i,j=1}^6 v_k w_i w_j \left. \frac{\partial^2 f_k}{\partial x_i \partial x_j} \right|_{E_1}, \\ \hat{b} &= \sum_{k,i=1}^6 v_k w_i \left. \frac{\partial^2 f_k}{\partial x_i \partial \beta_L} \right|_{E_1}. \end{aligned}$$

We use the center manifold approach on the model system (22). Let  $S = x_1, I_L = x_2, P_L = x_3, R_L = x_4, S_V = x_5$ , and  $I_V = x_6$ . Then  $N = x_1 + x_2 + x_3 + x_4$  and  $N_V = x_5 + x_6$  so that

$$\begin{aligned} x_1' &= f_1 = \Lambda - \frac{\beta_L c_L m x_6 x_1}{x_1 + x_2 + x_3 + x_4} - \mu x_1, \\ x_2' &= f_2 = \frac{\beta_L c_L m x_6 x_1}{x_1 + x_2 + x_3 + x_4} - \sigma \alpha_1 x_2 \\ &\quad - (1 - \sigma) \alpha_1 x_2 - (\mu + d_L) x_2, \\ x_3' &= f_3 = (1 - \sigma) \alpha_1 x_2 - (\alpha_2 + \theta) x_3 - \mu x_3, \\ x_4' &= f_4 = \sigma \alpha_1 x_2 + (\alpha_2 + \theta) x_3 - \mu x_4, \\ x_5' &= f_5 = \Lambda_L - \frac{\beta_V c_L (x_2 + x_3) x_5}{x_1 + x_2 + x_3 + x_4} - \mu_V x_5, \\ x_6' &= f_6 = \frac{\beta_V c_L (x_2 + x_3) x_5}{x_1 + x_2 + x_3 + x_4} - \mu_V x_6. \end{aligned}$$

The associated non-zero partial derivatives of  $f_i = (f_1, f_2, f_3, f_4, f_5, f_6)^T$  at  $E_1$  are given by

$$\begin{aligned} \frac{\partial^2 f_2}{\partial x_2 \partial x_6} &= \frac{\partial^2 f_2}{\partial x_3 \partial x_6} = \frac{\partial^2 f_2}{\partial x_4 \partial x_6} = \frac{\partial^2 f_2}{\partial x_6 \partial x_2} = \frac{\partial^2 f_2}{\partial x_6 \partial x_3} \\ &= \frac{\partial^2 f_2}{\partial x_6 \partial x_4} = -\frac{\mu m c_L \beta_L}{\Lambda}, \\ \frac{\partial^2 f_6}{\partial x_1 \partial x_1} &= \frac{\partial^2 f_6}{\partial x_1 \partial x_3} = \frac{\partial^2 f_6}{\partial x_2 \partial x_1} = \frac{\partial^2 f_6}{\partial x_2 \partial x_4} = \frac{\partial^2 f_6}{\partial x_3 \partial x_1} \\ &= \frac{\partial^2 f_6}{\partial x_3 \partial x_4} = \frac{\partial^2 f_6}{\partial x_4 \partial x_2} = \frac{\partial^2 f_6}{\partial x_4 \partial x_3} = -\frac{\mu^2 c_L \beta_V \Lambda_V}{\Lambda^2 \mu_V}, \end{aligned}$$

$$\begin{aligned} \frac{\partial^2 f_6}{\partial x_2 \partial x_2} &= \frac{\partial^2 f_6}{\partial x_2 \partial x_3} = \frac{\partial^2 f_6}{\partial x_3 \partial x_2} = \frac{\partial^2 f_6}{\partial x_3 \partial x_3} = -\frac{2\mu^2 c_L \beta_V \Lambda_V}{\Lambda^2 \mu_V}, \\ \frac{\partial^2 f_6}{\partial x_2 \partial x_5} &= \frac{\partial^2 f_6}{\partial x_3 \partial x_5} = \frac{\partial^2 f_6}{\partial x_5 \partial x_2} = \frac{\partial^2 f_6}{\partial x_5 \partial x_3} = \frac{\mu c_L \beta_L}{\Lambda}. \end{aligned}$$

Using the above expressions, the coefficients  $\hat{a}$  is given by

$$\begin{aligned} \hat{a} &= v_2 \sum_{i,j=1}^6 w_i w_j \frac{\partial^2 f_2}{\partial x_i \partial x_j} + v_6 \sum_{i,j=1}^6 w_i w_j \frac{\partial^2 f_6}{\partial x_i \partial x_j} \\ &= \frac{2v_2 w_2^2 d_L (\mu + d_L + \alpha_1)}{\Lambda} \\ &\quad \left[ 1 - \frac{(\mu + \alpha_1)}{d_L} \mathcal{R}_2 - \frac{\mu c_L \beta_V (\theta + \mu + (1 - \sigma) \alpha_1 + \alpha_2)}{\mu_V (\theta + \mu + \alpha_2)} \right]. \end{aligned}$$

For the sign of  $\hat{b}$ , we chose  $\beta_L$  as the bifurcation parameter. The associated non-zero partial derivatives of  $f_i$  at  $E_1$  are given by

$$\frac{\partial^2 f_1}{\partial x_6 \partial \beta_L} = -m c_L, \quad \frac{\partial^2 f_2}{\partial x_6 \partial \beta_L} = m c_L,$$

so that

$$\begin{aligned} \hat{b} &= v_2 w_6 \frac{\partial^2 f_2}{\partial x_6 \partial \beta_L} \\ &= \frac{\mu m c_L^2 \beta_V \Lambda_V (\alpha_1(1 - \sigma) + \alpha_2 + \theta + \mu)}{\Lambda \mu_V^2 (\alpha_2 + \theta + \mu)} v_2 w_2. \end{aligned}$$

It is seen that  $\hat{b}$  is always positive, while  $\hat{a}$  can either be positive or negative. Depending on the signs of  $\hat{a}$  and  $\hat{b}$ , we establish the following lemmas:

**Lemma 6.** *If  $\hat{a} < 0$  and  $\hat{b} > 0$ , then the VL sub-model model (22) undergoes forward bifurcation which occurs at  $\mathcal{R}_2 = 1$ .*

**Lemma 7.** *If  $\hat{a} > 0$  and  $\hat{b} > 0$ , then the VL sub-model model (22) undergoes backward bifurcation which occurs at  $\mathcal{R}_2 = 1$ .*

Hence, the positivity of  $\hat{a}$  offers the threshold circumstance for the phenomenon of backward bifurcation.

## 5. The full visceral leishmaniasis and tuberculosis co-infection model

In this section, we investigate the dynamical properties of the model (6). For convenience, we introduce the following new parameters:

$$\begin{aligned} \zeta_1 &= \kappa + \mu, \\ \zeta_2 &= p + \mu + d_L, \\ \zeta_3 &= \alpha_1 + \mu + d_L, \\ \zeta_4 &= \alpha_2 + \theta + \mu, \\ \zeta_5 &= \mu + d_T + d_L. \end{aligned} \tag{40}$$

### 5.1. The disease-free equilibrium

The disease-free equilibrium (EE) of the full model (6) is given as

$$E_{F1} = \left( S, E_T, I_T, R_T, I_L, P_L, R_L, I_{TL}, S_V, I_V \right) = \left( \frac{\Lambda}{\mu}, 0, 0, 0, 0, 0, 0, 0, \frac{\Lambda_V}{\mu_V}, 0 \right). \tag{41}$$

We now use the next-generation matrix approach to compute the basic reproduction of the model (6). For this purpose, we set  $X = (E_T, I_T, R_T, I_L, P_L, R_T, I_{TL}, S, I_V, S_V)^T$  and rewrite the model (6) in the matrix form

$$\frac{dX}{dt} = \mathcal{F}(X) - \mathcal{V}(X), \tag{42}$$

where

$$\mathcal{F} = \begin{pmatrix} \lambda_T S \\ 0 \\ 0 \\ \lambda_L S + \lambda_L R_T \\ 0 \\ 0 \\ 0 \\ 0 \\ \lambda_V S_V \\ 0 \end{pmatrix}, \text{ and } \mathcal{V} = \begin{pmatrix} \zeta_1 E_T + \psi \lambda_T E_T - qf \lambda_T R_T - \lambda_T R_L \\ -\kappa E_T - \psi \lambda_T E_T - q(1-f)\lambda_T R_T + \zeta_2 I_T + \lambda_L I_T \\ -p I_T - \epsilon E_T + qf \lambda_T R_T + q(1-f)\lambda_T R_T + \lambda_L R_T + \mu R_T \\ \zeta_3 I_L + \lambda_T I_L \\ -(1-\sigma)\alpha_1 I_L + \zeta_4 P_L \\ -\sigma \alpha_1 I_L + \lambda_T R_L - (\alpha_2 + \theta)P_L + \mu R_L \\ -\lambda_L I_T - \lambda_T I_L + \zeta_5 I_{TL} \\ -\Lambda + \lambda_T S + \lambda_L S + \mu S \\ \mu_V I_V \\ -\Lambda_V + \lambda_V S_V + \mu_V S_V \end{pmatrix} \tag{43}$$

We carry out the remainder of the calculations as before. The dominant eigenvalues of  $FV^{-1}$  are

$$\begin{cases} \mathcal{R}_1 = \frac{\beta_{TC}\kappa}{(\mu + \kappa)(\mu + d_T + p)}, \\ \mathcal{R}_2 = \sqrt{\frac{\mu m c_L^2 \beta_L \beta_V \Lambda_V (\alpha_1 (1 - \sigma) + \alpha_2 + \theta + \mu)}{\Lambda \mu_V^2 (\alpha_2 + \theta + \mu) (\alpha_1 + d_L + \mu)}}. \end{cases} \tag{44}$$

and these correspond to the reproduction numbers for the TB transmission model and the leishmaniasis transmission model, respectively. Thus, the basic reproduction number,  $\mathcal{R}_0$ , for the full model (6) is given by

$$\mathcal{R}_0 = \max\{\mathcal{R}_1, \mathcal{R}_2\}. \tag{45}$$

**Theorem 5.** *The disease-free equilibrium point  $E_{F1}$  of the full model (6) is locally asymptotically stable if  $\mathcal{R}_0 < 1$  and unstable when  $\mathcal{R}_0 > 1$ .*

### 5.2. Bifurcation parameters

The TB and VL-only sub-models are shown to exhibit the phenomenon of backward bifurcation and consequently, the full co-infection model will exhibit the same feature. Below, we derive the bifurcation parameters for the full co-infection model (6). Let  $S = x_1, E_T = x_2, I_T = x_3, R_T = x_4, I_L = x_5, P_L = x_6, R_L = x_7, I_{TL} = x_8, S_V = x_9,$  and  $I_V = x_{10}$ . Hence,

$$N^c = x_1 + x_2 + x_3 + x_4 + x_5 + x_6 + x_7 + x_8, \tag{46}$$

$$N_V^c = x_9 + x_{10}. \tag{47}$$


Letting  $X = (x_1, x_2, \dots, x_{10})^T$ , the full co-infection model (6) can be written in the form  $\frac{dX}{dt} = F(X)$ , where  $F = (f_1, f_2, \dots, f_{10})$ , as

$$\begin{aligned} \dot{x}_1 &= f_1 = \Lambda - \lambda_T^c x_1 - \lambda_L^c x_1 - \mu x_1, \\ \dot{x}_2 &= f_2 = \lambda_T^c x_1 - \kappa x_2 - \psi \lambda_T^c x_2 + qf \lambda_T^c x_4 + \lambda_T^c x_7 - \mu x_2, \\ \dot{x}_3 &= f_3 = \kappa x_2 + \psi \lambda_T^c x_2 + q(1-f)\lambda_T^c x_4 - p x_3 - \lambda_L^c x_3 - (\mu + d_T)x_3, \\ \dot{x}_4 &= f_4 = p x_3 - qf \lambda_T^c x_4 - q(1-f)\lambda_T^c x_4 - \lambda_L x_4 - \mu x_4, \\ \dot{x}_5 &= f_5 = \lambda_L^c x_1 + \lambda_L^c x_4 - \sigma \alpha_1 x_5 - (1 - \sigma)\alpha_1 x_5 - \lambda_T^c x_5 - (\mu + d_L)x_5, \\ \dot{x}_6 &= f_6 = (1 - \sigma)\alpha_1 x_5 - (\alpha_2 + \theta)x_6 - \mu x_6, \\ \dot{x}_7 &= f_7 = \sigma \alpha_1 x_5 - \lambda_T^c x_7 + (\alpha_2 + \theta)x_6 - \mu x_7, \\ \dot{x}_8 &= f_8 = \lambda_L^c x_3 + \lambda_T^c x_5 - (\mu + d_T + d_L)x_8, \\ \dot{x}_9 &= f_9 = \Lambda_V - \lambda_V^c x_9 - \mu_V x_9, \\ \dot{x}_{10} &= f_{10} = \lambda_V^c x_9 - \mu_V x_{10}, \end{aligned}$$

and

$$\lambda_T^c = \frac{\beta_{TC} x_3}{N^c}, \quad \lambda_L^c = \frac{\beta_{LC} m x_{10}}{N^c}, \quad \text{and} \quad \lambda_V^c = \frac{\beta_{VC} (x_5 + x_6)}{N^c}.$$


The Jacobian matrix of the system above at the DFE point  $E_{F1}$  is given by



$$J_{F1} = \begin{pmatrix} -\mu & 0 & -\beta_T c_T & 0 & 0 & 0 & 0 & 0 & 0 & -\beta_L c_L m \\ 0 & -\zeta_1 & \beta_T c_T & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \kappa & -\zeta_2 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & p & -\mu & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\zeta_3 & 0 & 0 & 0 & 0 & \beta_L c_L m \\ 0 & 0 & 0 & 0 & (1-\sigma)\alpha_1 & -\zeta_4 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & \sigma\alpha_1 & \alpha_2 + \theta & -\mu & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & 0 & -\zeta_5 & 0 & 0 \\ 0 & 0 & 0 & 0 & -\frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & -\frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & 0 & 0 & -\mu_V & 0 \\ 0 & 0 & 0 & 0 & \frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & \frac{\mu c_L \beta_V \Lambda_V}{\Lambda \mu_V} & 0 & 0 & 0 & -\mu_V \end{pmatrix}. \tag{48}$$

By computing the eigenvalues of the Jacobian  $J_{F1}$ , it can be shown that  $\mathcal{R}_0 = \max\{\mathcal{R}_1, \mathcal{R}_2\}$ , where  $\mathcal{R}_1$  and  $\mathcal{R}_2$  are as previously defined.  $\mathcal{R}_0 = \max\{\mathcal{R}_1, \mathcal{R}_2\}$ , hence, there is no competitive exclusion and the two diseases amplify each other. Thus, when  $\mathcal{R}_1 > 1$  and  $\mathcal{R}_2 > 1$ , there is always co-existence no matter which of the reproduction numbers is greater. Although

$\mathcal{R}_0$  does not combine the two reproduction numbers, by only studying the two diseases in isolation, we would miss the dual TB-visceral leishmaniasis co-infection, which has different dynamics to that of TB-only and visceral leishmaniasis only sub-models. Some additional insights are derived from studying the interaction of the two diseases, hence the full model. If  $\max\{\mathcal{R}_1, \mathcal{R}_2\} = \mathcal{R}_1$ , then,



from Theorem 2, the TB-VL co-infection model exhibits backward bifurcation for values of  $\mathcal{R}_1$  such that Lemma 5 holds.

On the contrary, if  $\max\{\mathcal{R}_1, \mathcal{R}_2\} = \mathcal{R}_2$ , and choosing  $\beta_L$  as the bifurcation parameter, then, the phenomenon of backward bifurcation occurs for values of  $\mathcal{R}_2$  such that Lemma 7 holds. Consequently, the full model will also exhibit the phenomenon of backward bifurcation when  $\mathcal{R}_0 = 1$ .

### 5.3. Endemic equilibrium

The endemic equilibrium  $E_4$  of the full model system (6) is given by

$$\begin{aligned}
 S_2 &= \frac{\Lambda}{\lambda_T^* + \lambda_L^* + \mu}, \\
 I_{T2} &= \frac{(\kappa + \psi)(q\lambda_T^* + \lambda_L^* + \mu)E_{T2}}{(q\lambda_T^* + \lambda_L^* + \mu)(p + \lambda_L^* + \mu + d_T) - q(1-f)p\lambda_T^*}, \\
 R_{T2} &= \frac{p(\kappa + \psi)(q\lambda_T^* + \lambda_L^* + \mu)E_{T2}}{\left[ (q\lambda_T^* + \lambda_L^* + \mu) \left[ (q\lambda_T^* + \lambda_L^* + \mu)(p + \lambda_L^* + \mu + d_T) - q(1-f)p\lambda_T^* \right] \right]}, \\
 I_{L2} &= \frac{\lambda_T^* S_2 + \lambda_L^* R_{T2}}{\alpha_1 + \lambda_T^* + \mu + d_T}, \\
 P_{L2} &= \frac{\alpha_1(1 - \sigma)(\lambda_L^* S_2 + \lambda_L^*)}{(\alpha_2 + \theta + \mu)(\alpha_1 + \lambda_T^* + \mu + d_T)}, \\
 R_{L2} &= \frac{\sigma \alpha_1 I_{L2} + (\alpha_2 + \theta)P_{L2}}{\lambda_T^* + \mu}, \\
 I_{TL2} &= \frac{\lambda_L^* I_{T2} + \lambda_T^* I_{L2}}{\mu + d_T + d_L},
 \end{aligned}$$

$$\begin{aligned}
 S_{V2} &= \frac{\Lambda_V}{\mu_V + \lambda_V^*}, \\
 I_{V2} &= \frac{\lambda_V^* \Lambda_V}{(\mu_V + \lambda_V^*) \mu_V}.
 \end{aligned}$$

Solving for  $E_{T2}$  in


$$\lambda_T^* S_2 - (\kappa + \psi \lambda_T^* + \mu) E_{T2} + qf \lambda_T^* R_{T2} + \lambda_T^* R_{L2} = 0.$$

The forces of infection at  $E_4$  are given by,

$$\begin{aligned}
 \lambda_T^* &= \frac{\beta_T c_T I_{T2}}{N^c}, \quad \lambda_L^* = \frac{\beta_L c_L m I_{V2}}{N^c}, \quad \text{and} \\
 \lambda_V^* &= \frac{\beta_V c_L (I_{L2} + I_{TL2} + P_{L2})}{N^c}.
 \end{aligned}$$

### 6. Simulations and results



In this section, we provide simulation results for the TB-only model in Figure 2, the VL-only model in Figure 3, and the full VL-TB co-infection model in Figure 4. We performed the simulations using the in-built function ODE45 in MATLAB (MathWorks, Natick, MA, USA) [35], with the aim of understanding the long-term dynamics of the models and checking if it is consistent with the theoretical results. For this purpose, we used the parameter values given in Table 1. We observe from Figures 2–4 that the DFE points are locally asymptotically stable for each model. For the TB-only model,  $\mathcal{R}_1 < 1$  and hence, the DFE point  $E_0 = (S_0, E_{T0}, I_{T0}, R_{T0}) =$



$\left(\frac{\Lambda}{\mu}, 0, 0, 0\right)$  is locally asymptotically stable. This implies that the epidemic will be eradicated. The solutions of the model 9 are depicted in Figure 2. Similarly, the VL-only model DFE point  $Q_0 = \left(S, I_L, P_L, R_L, S_V, I_V\right) = \left(\frac{\Lambda}{\mu}, 0, 0, 0, \frac{\Lambda_V}{\mu_V}, 0\right)$  is

locally asymptotically stable. This implies that the epidemic will be eradicated  $\mathcal{R}_2 < 1$  as depicted in 1. Therefore, Figures 2–4 are consistent with theoretical results obtained for each case, and these results imply that the disease will be eliminated.





## 6.1. Bifurcation analysis

### 6.1.1. TB-only model

The combined effect of  $\beta_T$  and  $d_T$  on the values of  $\mathcal{R}_1$  are explored next to determine the threshold conditions of these parameters at which the TB-only model exhibits backwards and forward bifurcations. The  $\mathcal{R}_1$  contours, see Figure 5, show an increase in  $\mathcal{R}_1$  as  $\beta_T$  and  $d_T$  increase.

### 6.1.2. VL-only model


The combined effect of  $\beta_L$ ,  $d_L$ ,  $\sigma$ ,  $\alpha_1$ , and  $\alpha_2$  on the values of  $\mathcal{R}_2$  are explored next to determine the threshold conditions of these parameters at which the VL-only model exhibits backward and forward bifurcations.

The  $\mathcal{R}_2$  contours, see Figure 6, show an increase in  $\mathcal{R}_2$  as  $\beta_L$  increases and  $d_L$  decreases. In Figure 7, we observe that  $\mathcal{R}_2$  decrease as  $\sigma_1$ ,  $\alpha_1$ , and  $\alpha_2$  increase. All the  $\mathcal{R}_2$  contours are less than unity, which signifies that these values of  $\sigma_1$ ,  $\alpha_1$ , and  $\alpha_2$  (and other fixed parameters) will lead to the elimination of VL from the community (in line with Theorem 3). However, the analysis verifies that the parameters  $\sigma_1$ ,  $\alpha_1$ , and  $\alpha_2$  are the cause of occurring backward bifurcation in the VL model whenever  $\mathcal{R}_2 < 1$  as guaranteed by Lemma 6-7.

## 7. Conclusion

In developing nations, visceral leishmaniasis (VL) and tuberculosis (TB) co-infection is becoming a growing public health concern. Leishmaniasis infection alters the protective immunologic

response to Bacillus Calmette-Guerin (BCG) vaccine against tuberculosis [36]. Tuberculosis is an immuno-suppressive disease that causes latent leishmaniasis to proceed to clinical leishmaniasis, and VL can provoke latent TB infection to TB disease [36]. In this study, we developed and analyzed a model that describes transmission dynamics of visceral leishmaniasis and tuberculosis co-infection. Firstly, we analyzed the VL and TB sub-models separately. The reproduction number for each sub-model was calculated by the next-generation matrix approach. The local stability properties of the sub-models were studied. We observed that when the associated reproduction numbers ( $\mathcal{R}_1$ ) for the TB-only model and ( $\mathcal{R}_2$ ) for the VL-only model are less than unity, respectively, the model exhibits bifurcation. We observed that  $\mathcal{R}_0 = \max\{\mathcal{R}_1, \mathcal{R}_2\}$ , hence, there is no competitive exclusion and the two diseases amplify each other. Thus, when  $\mathcal{R}_1 > 1$  and  $\mathcal{R}_2 > 1$ , there is always co-existence no matter which of the reproduction numbers is greater. If  $\max\{\mathcal{R}_1, \mathcal{R}_2\} = \mathcal{R}_1$ , then the TB-VL co-infection model exhibits backward bifurcation at which  $\mathcal{R}_1 = 1$ . Furthermore, if  $\max\{\mathcal{R}_1, \mathcal{R}_2\} = \mathcal{R}_2$ , and choosing the transmission probability  $\beta_L$  as the bifurcation parameter, then the phenomenon of backward bifurcation occurs at  $\mathcal{R}_2 = 1$ . Consequently, the full model also exhibits the phenomenon of backward bifurcation when  $\mathcal{R}_0 = 1$ . The implication of this is that a stable endemic equilibrium coexists with a stable disease-free equilibrium whenever the fundamental reproduction number is less than unity. This study makes the argument that lowering the fundamental reproduction rate alone is insufficient to eradicate tuberculosis, leishmaniasis, and/or visceral leishmaniasis and tuberculosis co-infection models. The thresholds and equilibrium quantities for the models are determined, and



their stability is analyzed. Finally, some numerical simulations are carried out to illustrate some of our theoretical results. The proposed model is not exhaustive and can be extended in various ways. As a future work, we intend to expand this study to construct a VL-TB co-infection model with a reservoir host population which considers antiviral therapy for VL infection. We will also expand it to consider treatment for both latent and active TB.

## Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

## Author contributions

OE: methodology, investigation, resources, formal analysis, simulations, and writing-original draft. JM: methodology, investigation, supervision, and writing-review and editing. SS: methodology, investigation, formal analysis, simulations, and writing-original draft. PD: methodology and simulations. FO: investigation, resources, and writing-review and editing. All authors contributed to the article and approved the submitted version.

## Acknowledgments

OE acknowledge support from the DSI-NRF Centre of Excellence in Mathematical and Statistical Sciences (CoE-MaSS), South Africa. Opinions expressed and conclusions arrived at are those of the authors and are not necessarily to be attributed to the CoE-MaSS. OE was particularly grateful to Raphael Taiwo Aruleba (University of Cape Town) for the useful discussion that led to this article.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## References

- Zou L, Chen J, Ruan S. Modeling and analyzing the transmission dynamics of visceral leishmaniasis. *Math Biosci Eng.* (2017) 14:1585–604. doi: 10.3934/mbe.2017082
- Agyingi E, Wiandt T. Analysis of a model of leishmaniasis with multiple time lags in all populations. *Math Comput Appl.* (2019) 24:63. doi: 10.3390/mca24020063
- ELmojtaba IM. Mathematical model for the dynamics of visceral leishmaniasis-malaria co-infection. *Math Methods Appl Sci.* (2016) 39:4334–53. doi: 10.1002/mma.3864
- ELmojtaba IM, Mugisha JYT, Hashim MHA. Mathematical analysis of the dynamics of visceral leishmaniasis in the Sudan. *Appl Math Comput.* (2010) 217:2567–78. doi: 10.1016/j.amc.2010.07.069
- Biswas S. Mathematical modeling of Visceral Leishmaniasis and control strategies. *Chaos Solitons Fractals.* (2017) 104:546–56. doi: 10.1016/j.chaos.2017.09.005
- Patterson S, Wyllie S, Norval S, Stojanovski L, Simeons FRC, Auer JL, et al. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. *eLife.* (2016) 5:e09744. doi: 10.7554/eLife.0974
- van Griensven J, Mohammed R, Ritmeijer K, Burza S, Diro E. Tuberculosis in visceral leishmaniasis-human immunodeficiency virus coinfection: an evidence gap in improving patient outcomes? *Open Forum Infect Dis.* 5:ofy059. doi: 10.1093/ofid/ofy059
- Li XX, Zhou XN. Co-infection of tuberculosis and parasitic diseases in humans: a systematic review. *Parasit Vectors.* (2013) 6:79. doi: 10.1186/1756-3305-6-79
- Shweta SB, Gupta AK, Murti K, Pandey K. Co-infection of visceral leishmaniasis and pulmonary tuberculosis: a case study. *Asian Pac J Trop Dis.* (2014) 4:57–60. doi: 10.1016/S2222-1808(14)60315-7
- Croft SL, Coombs GH. Leishmaniasis—current chemotherapy and recent advances in the search for novel drugs. *Trends Parasitol.* (2003) 19:502–8. doi: 10.1016/j.pt.2003.09.008
- Egbelowo O, Sarathy JP, Gausi K, Zimmerman MD, Wang H, Wijnant G-J, et al. Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits. *Antimicrob Agents Chemother.* (2021) 65:e00024-21. doi: 10.1128/AAC.00024-21
- Keeling MJ, Danon L. Mathematical modelling of infectious diseases. *Br Med Bull.* (2009) 92:33–42. doi: 10.1093/bmb/ldp038
- Grassly N, Fraser C. Mathematical models of infectious disease transmission. *Nat Rev Microbiol.* (2008) 6:477–87. doi: 10.1038/nrmicro1845
- van den Driessche P, Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Math Biosci.* (2002) 180:29–48. doi: 10.1016/s0025-5564(02)00108-6
- Castillo-Chavez C, Song B. Dynamical models of Tuberculosis and their applications. *Math Biosci Eng.* (2004) 1:361–404. doi: 10.3934/mbe.2004.1.361
- Nudee K, Chinviriyasit S, Chinviriyasit W. The effect of backward bifurcation in controlling measles transmission by vaccination. *Chaos Solitons Fractals.* (2019) 123:400–12. doi: 10.1016/j.chaos.2019.04.026
- Mwamtobe PM, Simelane SM, Abelman S, Tchuente JM. Optimal control of intervention strategies in malaria-tuberculosis co-infection with relapse. *Int J Biomath.* (2018) 11:1850017. doi: 10.1142/S1793524518500171
- Korobeinikov A. Lyapunov functions and global properties for SEIR and SEIS epidemic models. *Math Med Biol.* (2004) 21:75–83. doi: 10.1093/imammb/21.2.75
- Korobeinikov A. Lyapunov functions and global stability for SIR, SIRS, and SIS epidemiological models. *Appl Math Lett.* (2002) 15:955–60. doi: 10.1016/S0893-9659(02)00069-1
- Roop-O P, Chinviriyasit W, Chinviriyasit S. The effect of incidence function in backward bifurcation for malaria model with temporary immunity. *Math Biosci.* (2015) 265:47–64. doi: 10.1016/j.mbs.2015.04.008
- Hoang MT, Egbelowo OF. On the global asymptotic stability of a hepatitis B epidemic model and its solutions by nonstandard numerical schemes. *Bol Soc Math Mex.* (2020) 26:1113–34. doi: 10.1007/s40590-020-00275-2
- Rahman MU, Arfan M, Shah Z, Kumam P, Shutaywi M. Nonlinear fractional mathematical model of tuberculosis (TB) disease with incomplete treatment under Atangana-Baleanu derivative. *Alex Eng J.* (2021) 60:2845–56. doi: 10.1016/j.aej.2021.01.015
- Tang TQ, Jan R, Bonyah E, Shah Z, Alzahrani E. Qualitative analysis of the transmission dynamics of dengue with the effect of memory, reinfection, and vaccination. *Comput Math Methods Med.* (2022) 2022:7893570. doi: 10.1155/2022/7893570
- Zhang Z, Zeb A, Egbelowo OF, Erturk VS. Dynamics of a fractional order mathematical model for COVID-19 epidemic. *Adv Differ Equat.* (2020) 2020:420. doi: 10.1186/s13662-020-02873-w
- Egbelowo OF, Hoang MT. Global dynamics of target-mediated drug disposition models and their solutions by nonstandard finite difference method. *J Appl Math Comput.* (2021) 66:621–43. doi: 10.1007/s12190-020-01452-2
- Tang TQ, Shah Z, Jan R, Ebraheem A. Modeling the dynamics of tumor immune cells interactions via fractional calculus. *Eur Phys J Plus.* (2022) 137:367. doi: 10.1140/epjp/s13360-022-02591-0
- Shah Z, Jan R, Kumam P, Deebani W, Shutaywi M. Fractional dynamics of HIV with source term for the supply of new CD4+ T-cells depending on the viral load via caputo-fabrizio derivative. *Molecules.* (2021) 26:1806. doi: 10.3390/molecules26061806
- Susi H, Barres B, Pedro FV, Laine AL. Co-infection alters population dynamics of infectious disease. *Nat Commun.* (2015) 6:5975. doi: 10.1038/ncomms6975
- Roeger LI, Feng Z, Castillo-Chavez C. Modeling TB and HIV co-infections. *Math Biosci Eng.* (2009) 6:815–37. doi: 10.3934/mbe.2009.6.815
- Melese ZT, Alemneh HT. Enhancing reservoir control in the co-dynamics of HIV-VL: from mathematical modeling perspective. *Adv Differ Equat.* (2021) 2021:429. doi: 10.1186/s13662-021-03584-6
- Mtisi E, Rwezaura H, Tchuente JM. A mathematical analysis of malaria tuberculosis co-dynamics. *Discr Contin Dyn Syst Ser B.* (2009) 12:827–64. doi: 10.3934/dcdsb.2009.12.827
- Bhunu CP, Garira W, Mukandavire Z. Modeling HIV/AIDS and tuberculosis coinfection. *Bull Math Biol.* (2009) 71:1745–80. doi: 10.1007/s11538-009-9423-9
- Lakshmikantham V, Leela S, Martynuk AA. *Stability Analysis of Nonlinear Systems.* New York, NY; Basel: Marcel Dekker Inc. (1989).
- Winter PA, Jessop CL, Adewusi FJ. The complete graph: eigenvalues, trigonometrical unit-equations with associated t-complete-eigen sequences, ratios, sums and diagrams. *Asian J Math Sci Res.* (2015) 9:92–107.
- MATLAB. 9.7.0.1190202 (R2019b). Natick, MA: The MathWorks Inc. (2018).
- Thakur S, Joshi J, Kaur S. Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. *J Parasit Dis.* (2020) 44:253–72. doi: 10.1007/s12639-020-01212-w